OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Discovery is 79. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
AI-Supported Mammography “Safe,” Cuts Workload	6276
HLA-E:CD94–NKG2A Mediates Circulating Tumor Cell Immune Evasion	657
Mutation-Driven Alveolar Cell Reprogramming Dictates Lung Cancer Progression	338
Succinyl-CoA and Cobalamin Are Biomarkers That Improve Anal Cancer Screening	299
Human Tumor Cells Display an Oncogene-like Addiction to Aneuploidy	242
Q&A: Philip Greenberg on T Cells, IO's Future	240
Structure of the Tumor Stroma Predicts Invasive Breast Cancer Relapse	220
Shattered Chromosomes Undergo Mitotic Tethering during Chromothripsis	219
PARADIGM Identifies Associations between Drugs, the Microbiome, and Mortality	204
Air Pollution Promotes Oncogenic Expansion of Mutant Lung Progenitor Cells	201
Transposable Element Signatures Define Stages of T-cell Exhaustion	198
Probing Clonal Hematopoiesis in Liquid Biopsy	191
IL7 Genetic Variation Predicts Immune-Related Adverse Events	188
Low-Glycemic Diets Restrict Tumor Growth through Altered Lipid Metabolism	188
Collagen Receptor Implicated in Immune Exclusion	188
Drafting a Blueprint for European Cancer Research	185
Dendritic Cell Circadian Rhythm Governs the Antitumor Immune Response	179
Mouse Models Provide Insight into Factors Affecting BiTE Efficacy	170
Highlighted research articles	168
REFLECTions on Combination Therapies Empowered by Data Sharing	163
Proteostasis Network Modulation Promotes Resistance to KRAS Inhibitors	163
Highlighted research articles	157
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission	146
Convergence of Targeted and Immune Therapies for the Treatment of Oncogene-Driven Cancers	143
Adjuvant PD-1 Blockade in Resected Melanoma: Is Preventing Recurrence Enough?	140

PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway	139
Correction: Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms That Maintain High MYC Levels in Colorectal Cancer	139
Selpercatinib Shifts Treatment Paradigm for MTC and NSCLC	138
Cytosolic Phospholipase A2 Determines Intercellular Heterogeneity of Stress Granules and Chemotherapy Response	134
Exome Sequencing IDs Hidden Disease Variants	133
Intrinsic Properties of the Lymph Node Render It Immunologically Susceptible to Metastasis	132
GIST: Molecular Profiling Suggests 2nd Therapy	128
Visualizing Cancer Heterogeneity at the Molecular and Cellular Levels: Lessons from Rosetta	128
A Guide to Extrachromosomal DNA: Cancer’s Dynamic Circular Genome	126
The 3D Revolution in Cancer Discovery	126
Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors	123
Combination Diagnostics: Adding Blood-Based ctDNA Screening to Low-Dose CT Imaging for Early Detection of Lung Cancer	123
Patterns of Oncogene Coexpression at Single-Cell Resolution Influence Survival in Lymphoma	122
Trispecifics Improve Immune-Cell Engagement	122
An NK-cell Therapy for CD30+ Lymphomas	121
Gut microbiota modulation through Akkermansia spp. supplementation increases CAR-T cell potency	121
p53 Gain-of-Function Mutation Induces Metastasis via BRD4-Dependent CSF-1 Expression	119
RAS Drives Malignancy through Altered Stem Cell/Microenvironment Cross-talk	119
A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy	118
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors	116
Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma	114
CHD2 Regulates Neuron–Glioma Interactions in Pediatric Glioma	112
Neuro-Mesenchymal Interaction Mediated by a β2-Adrenergic Nerve Growth Factor Feedforward Loop Promotes Colorectal Cancer Progression	111
Lymph Node Metastasis Induces Immune Tolerance and Distant Metastasis	109
Presurgery Plus Postsurgery Immunotherapy Ups Survival in NSCLC	108
Chronic Inflammation Drives TP53-Mutant Leukemic Evolution	105
Multicellular Spatial Organization Determines Immunotherapy Response	105
In This Issue	101
Amgen Deal Nets Potential Cancer Therapies	101
Response to Low Antigen Density Is Improved by HLA-Independent T-cell Receptors	101
The Proteasome Regulator PSME4 Modulates Antitumor Immunity	100
Intestinal Microbiome Inhibits CD8+ T Cells via the Calcineurin–NFAT Axis	100
Tumor-Derived Extracellular Vesicles and Particles Inhibit Liver Function	100
New Strategy May Thwart Glioblastoma Resistance	99
FMRP Depletion Reprograms an Immunosuppressive Microenvironment	99
TILs Outperform Ipilimumab in Melanoma	98
Hyperactivation of Oncogenic Pathways Hinders Cancer Cell Survival	97
Lymph Node–Specific IFNγ Levels Affect CD8+ T-cell Priming against Tumors	95
Revumenib Is Safe and Efficacious, but MEN1 Mutations Mediate Resistance	93
What's Next for Sotorasib in NSCLC?	92
Aged Lungs Enable Metastatic Outgrowth of Dormant Melanoma Cells	91
Biomarker Testing Falls Short in NSCLC	88
In This Issue	86
Moving Spatially Resolved Multiplexed Protein Profiling toward Clinical Oncology	84
Noninvasive and Multicancer Biomarkers: The Promise of LINE-1 Retrotransposons	84
Bridging the Gap between Diseases of the Stomach and Lower Esophagus	84
Cancer in the Prime of Life: Etiologic Insights and Supportive Oncologic Interventions for the Rising Burden of Young Adult Cancer	84
Harnessing Mitochondrial Mutations to ATAC Clonal Evolution in CLL	83
New Immunotherapy Combinations Enter the Battlefield of Malignant Mesothelioma	83
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients	82

Beneath the Surface: Neoantigens beyond Chromosomal DNA Mutations	82
Akk Abundance Alters Survival in Patients with NSCLC on ICIs	82
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer	80
Rlf–Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer	79
Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy	79
Atypical Small Cell Lung Cancer: A New Malignancy Characterized by Chromothripsis, Carcinoid Tumors, and Wild-type RB1 and TP53	79